Posters presented at Fall Clinical Dermatology 2023 found that dupilumab had effective and safe results when received in a 5-year period for atopic dermatitis. Atopic dermatitis (AD) could be safely ...
* DUPIXENT ® is the only biologic medicine approved by Health Canada to treat moderate-to-severe atopic dermatitis. * Public reimbursement under the Ontario Exceptional Access Program and the New ...
Although injection site reactions were common occurrences in both the tralokinumab and dupilumab groups, tralokinumab caused ISRs more frequently. Tralokinumab caused more frequent injection site ...
The US Food and Drug Administration (FDA) has issued a complete response letter regarding the application for approval of dupilumab for the treatment of chronic spontaneous urticaria (CSU) in people ...
Dupilumab, a fully human monoclonal antibody, blocks interleukin-4 and interleukin-13 signaling, which have key roles in eosinophilic esophagitis. We conducted a three-part, phase 3 trial in which ...
Please provide your email address to receive an email when new articles are posted on . Patients with both chronic rhinosinusitis with nasal polyps and asthma experience greater disease severity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback